Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The initiative was announced at World Hypertension Congress, Chennai
The initiative aims to empower individuals to take proactive steps towards monitoring their health
Enables millions of Indians to monitor their vitals without the need of any additional device
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
The medicine was well tolerated, with no unexpected safety issue
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection 40 Units per 100 mL and 20 Units per 100 mL of PH Health Limited
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
Subscribe To Our Newsletter & Stay Updated
